Metsera (NASDAQ:MTSR) Releases Earnings Results

Metsera (NASDAQ:MTSR) issued its earnings results on Wednesday. The company reported ($3.52) EPS for the quarter, Zacks reports.

Metsera Price Performance

MTSR opened at $29.16 on Wednesday. Metsera has a fifty-two week low of $23.08 and a fifty-two week high of $32.81.

Analysts Set New Price Targets

Several analysts have recently commented on MTSR shares. Guggenheim started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective on the stock. Evercore ISI assumed coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating on the stock. Cantor Fitzgerald started coverage on Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating for the company. Finally, Bank of America assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $38.00 target price on the stock.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.